The transcription factor SOX10 is essential for survival and proper differentiation of neural crest cell lineages, where it plays an important role in the generation and maintenance of melanocytes. SOX10 is also highly expressed in melanoma tumors, but a role in disease progression has not been established. Here, we report that melanoma tumor cell lines require wild-type SOX10 expression for proliferation and SOX10 haploinsufficiency reduces melanoma initiation in the metabotropic glutamate receptor 1 (Grm1  Tg ) transgenic mouse model. Stable SOX10 knockdown in human melanoma cells arrested cell growth, altered cellular morphology, and induced senescence. Melanoma cells with stable loss of SOX10 were arrested in the G 1 phase of the cell cycle, with reduced expression of the melanocyte determining factor microphthalmia-associated transcription factor, elevated expression of p21WAF1 and p27KIP2, hypophosphorylated RB, and reduced levels of its binding partner E2F1. As cell-cycle dysregulation is a core event in neoplastic transformation, the role for SOX10 in maintaining cell-cycle control in melanocytes suggests a rational new direction for targeted treatment or prevention of melanoma. Cancer Res; 73(18); 5709-18. Ó2013 AACR.
Introduction
Melanocytes are melanin-producing cells of neural crest origin located in the dermis and epidermis of the skin, the eye, the inner ear, and mucosal membranes. During development, differentiating melanocytes migrate from the neural tube to these distinct anatomic locations, each with unique cellular environments and potential for UV exposure. Malignancy of melanocytes results in melanoma, an aggressive and often fatal cancer. Moreover, melanoma incidence is increasing worldwide; the American Cancer Society describes melanoma as a disease affecting a wide-range of ages and projects diagnosis of approximately 76,600 new cases in 2013 (1) . Classification of melanoma subtypes incorporates anatomic melanocyte location, degree of sun exposure, and histopathology in addition to genetic categorization based upon mutations in the mitogen-activated protein kinase (MAPK) signaling pathway components BRAF, NRAS, KIT, GNA11, and GNAQ (2) (3) (4) (5) . While recent targeted therapies to mutant BRAF hold promise, the majority of treated individuals with melanoma ultimately exhibit chemoresistance (6) . Given the heterogeneity exhibited in melanoma, not only between tumor subtypes, but also the molecular diversity within individual lesions (7) , there is a paramount need to identify and functionally assess additional genes fundamental to the regulation of melanoma growth and metastasis.
Increasing correlations are being discovered between genes that regulate developmental processes and the genes and signaling pathways mediating tumor progression through proliferation, invasion, and metastasis. Specification, survival, and differentiation of neural crest-derived lineages including melanocytes is dependent on SOX10 [SRY (sex-determining region Y)-box 10], a member of the high mobility group (HMG) domain SOX family of transcription factors. The approximately 50 known heterozygous germline mutations in SOX10 have been linked to developmental neurocristopathies Waardenburg syndrome (types II and IV) and PCWH (peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease; ref. 8) . SOX10 regulates many targets during neural crest development, including microphthalmia-associated transcription factor (MITF), which is necessary for normal melanocyte development. The regulation of MITF by SOX10 has implications in melanomagenesis, as MITF mutations and amplifications have been identified in a subset of melanomas (9, 10) . MITF activates genes involved in melanocyte survival, such as BCL2 (11) and plays a key role in cell cycle via regulation of cyclin-dependent kinase inhibitor 2A (INK4A or CDKN2A), cyclin-dependent kinase inhibitor 1B (p27 or CDKN1B), and p53 (TP53; refs. [12] [13] [14] .
In this study, we evaluate the role of SOX10 in melanomagenesis. We examine the mutation spectrum of SOX10 in primary and metastatic melanoma tumor samples from multiple histologic subtypes and discover a low frequency of mutations. We assess the effects of reduced SOX10 levels on melanoma growth and survival and we show a G 1 cell-cycle arrest results from a loss of SOX10. We also confirm SOX10 expression is fundamental for melanomagenesis in vivo by showing that a reduction in SOX10 expression reduces tumor formation in the Grm1 Tg melanoma mouse model. Together, these results indicate reducing SOX10 levels has fateful consequences for melanoma formation and expansion, suggesting SOX10 is a promising target for melanoma treatment. Table  S1 ) were designed using NetPrimer (http://www.premierbiosoft.com/netprimer/index.html) and synthesized by Invitrogen. SOX10-coding regions were amplified with TaKaRa LA Taq DNA Polymerase (Takara Bio) and sequencing carried out using BigDye Terminator v3.1 (Applied Biosystems). Sequence data were analyzed with Sequencher 4.9 Software (Gene Codes Corporation).
Materials and Methods

PCR
Cell Culture, siRNA transfection, and generation of stable short hairpin RNA lines UACC melanoma cell line isolations were described previously (15); 0002-ARM-032702 (0002-ARM, IRB protocol number 97-79), and 0380-MMU-071802 (0380-MMU) cell lines were generated from patients at the Maryland Melanoma Center following standard surgical consent (16) . Cell lines were maintained at 37 C with 5% CO 2 in Dulbecco's Modified Eagle Medium (UACC 1022) or Iscove's Modified Dulbecco's Medium (0380-MMU and 0002-ARM) supplemented with 10% FBS and 2 mmol/L L-glutamine (Invitrogen). To generate stable short hairpin RNA (shRNA) cell lines, melanoma cells were infected with pLKO1 lentiviral shRNA supernatant produced in 293T packaging cell line as described previously (17) . Infected cells were selected with dose of puromycin antibiotic and cultured for 3 to 6 days before knockdown screening and functional assays. For transient transfection of siRNA duplexes, cells were treated with siRNA-Lipofectamine 2000 reagent complexes for 72 hours before harvesting. RNAi 27mer duplexes targeting SOX10 were synthesized by Integrated DNA Technologies. siRNA sequences used in this analysis were: SOX10si_1-5 0 AGACAAAGAAUGAGGUUAUUGGCACAG-3 0 , SOX10si_2-5 0 -GGUGCAACAGUCAACCUCCUUCUCCUC-3 0 , and nonsilencing control-siGENOME nontargeting siRNA pool #2 (Thermo Scientific).
Immunoblotting
Protein gels and Western blots were conducted using standard protocols. Primary antibodies were: monoclonal SOX10 (R&D Systems #MAB2864), monoclonal a-Tubulin (Calbiochem #CP06), total RB and Phospho-RB Ser807/811 antibody Kit (Cell Signaling Technology #9969), polyclonal E2F1 (Cell Signaling Technology #3742), monoclonal p16 (F-12 Santa Cruz Biotechnology #sc-1661), monoclonal p21 Waf1/Cip1 (Cell Signaling Technology #2946), monoclonal cyclin D1 (BD Pharmingen #G124-326), monoclonal p27 (Santa Cruz Biotechnology #sc-1641), polyclonal CDK2, CDK4, and CDK6 (Santa Cruz Biotechnology #sc-163, sc-601, and sc-177, respectively), and monoclonal MITF (generously provided by Heinz Arnheiter, NIH, Bethesda, MD). HRP-conjugated secondary antibody were from Jackson ImmunoResearch Laboratories.
Proliferation assay
Melanoma cell lines stably expressing nonsilencing or SOX10-specific shRNA were examined by seeding into 12-well plates (15,000 cells/well) and culturing for 14 to 16 days. Cells were fed fresh growth media once a week. Samples were analyzed every 48 to 72 hours by Vi-CELL counter (Beckman Coulter). All samples were run in duplicate, in two or three independent assays.
Immunohistochemistry
Cells were seeded into 8-well chamber CC2-coated slides (Thermo Fisher Scientific) one day before staining. Cells were rinsed with 1Â PBS, fixed in 4% paraformaldehyde for 10 minutes, rinsed briefly with 1Â PBS 0.1% Tween, then permeabilized with 0.1% Triton for 10 minutes. Following a 30-minute block in 1mg/mL bovine serum albumin (Sigma #A3059), cells were incubated 2 hours with primary antibodies in block (anti-SOX10, Santa Cruz, sc-17342; anti-HP1b, Millipore, MAB3448). Cells were then rinsed and incubated for 20 minutes in Alexa 488 or 568 secondary antibodies (Invitrogen) diluted in block. Cells were rinsed before mounting with ProLong Gold mounting media with DAPI (Invitrogen). Cell images were taken on Zeiss AxioImager.D2 upright microscope with AxioVision 4.8 software (Carl Zeiss Microscopy).
Senescence-associated b-galactosidase staining
Cultured cells were plated into 6-well dishes one day before staining. Cells were fixed and stained as per the manufacturer's protocol (Senescence b-Galactosidase Staining Kit, Cell Signaling Technology #9860). Stained cells were imaged with a Zeiss Axio Observer inverted scope with differential interference contrast brightfield microscopy. Ten random images were collected and cells counted with ImageJ 1.45s software.
Staining was conducted one week after infection or 72 hours after transfection in triplicate.
Fluorescence-activated cell sorting
Cultured cells were harvested by trypsinization, counted, and 5 Â 10 5 cells were pelleted by centrifugation (1,000 rpm, 5 minutes). Cell pellets were resuspended in 500 mL propidium iodide and then incubated for 20 minutes at 37 C (NuCycl protocol; Exalpha Biologicals). Propidium iodide-stained cells were filtered and sorted on a FACS Calibur with 488 nm excitation (BD Biosciences).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was conducted on ABI 7500 (Applied Biosystems). RNA was isolated with RNeasy Mini Kits (Qiagen), three independent isolations were conducted for each sample. cDNA was generated with a Super Script III Kit (Invitrogen) as per the manufacturer's protocol. TaqMan gene expression assays (Applied Biosystems) for SOX10 (Hs00366918_m1), MITF (Hs00165156_m1), RB1 (Hs01078066_m1), p27 (Hs01597588), and E2F1 (Hs00153451_m1) were used with GAPDH (Hs02758991_g1) as reference gene. Alternatively, gene expression was measured with SYBR Green I PCR mix [15.2 mL diethyl pyrocarbonate (DEPC) water, 2.5 mL 10 Â PCR buffer (10), 2.5 mL 10 mmol/L dNTP, 1.5 mL dimethylsulfoxide, 0.5 mL SYBR Green I diluted 1:1,000 in DEPC water, 0.5 mL of 50 mmol/L forward and reverse primers, and 25 mL TaKaRa LA Taq DNA polymerase) for p21 (CDKN1A). Cycling conditions were: 94 C, 2 minutes; 40 cycles at 94 C, 10 seconds; 60 C, 30 seconds; and 70 C, 30 seconds. Standard curve analysis was conducted on each gene (ABI 7500 Fast System v1.4.0 Software) in triplicate for each biologic sample. Primer sequences used in this analysis (5 0 to 3 0 ) were: p21 (CDKN1A) forward, ACTCTCAGGGTCGAAAACGG and reverse, CCTCGCGCTTCCAGGACTG (18); GAPDH forward, CATGACCACAGTCCATGCCATCACT and reverse, TGAGGT-CCACCACCCTGTTGCTGTA (19) .
Mouse husbandry and phenotype scoring
Mice were maintained in NIH animal facilities and all procedures approved by the Institutional Animal Care and Use Committee in accordance with NIH guidelines. Grm1Tg (p18A4.B)1352Szc mice, hereafter Grm1
Tg (20) Tg/þ heterozygotes and double heterozygote mice were backcrossed to Grm1
Tg/þ heterozygotes to generate mice for analysis.
To quantitate the severity of melanoma progression in Grm1
Tg mice, detailed observation and photodocumentation was used to assign numerical scores of 0 to 4 to the ears for two independent criteria, pigmentation and raised tumor severity. For scoring pigmentation, 0 indicated no visible pigmented nevi on the ear and 4 indicated that 90% to 100% of the ear was covered in continuous pigmentation. For scoring degree to which nevi were raised, 0 indicated that any visible pigmentation was flat with no detectable increased thickness of the skin and 4 indicated a significant raised tumor that was becoming necrotic and warranted euthanasia. Ventral spotting was also scored using a scale of 0 to 4 (0 ¼ no ventral spotting; 4 ¼ severe ventral spotting extending dorsally) as previously described (24) .
Results
Assessment of somatic SOX10 mutations across melanoma subtypes
Melanoma can arise in different histologic locations, resulting in numerous subtypes with distinct protein expression patterns and genomic aberrations (25) . Previously, we identified intragenic mutations in the SOX10 locus in a subset of samples from both primary and metastatic melanoma (10) . To fully evaluate the contribution of SOX10 mutations to melanoma progression, we expanded our analysis of SOX10 coding variations with an additional 153 melanoma samples representing various histologic subtypes (Table 1) . Only one novel SOX10 alteration was observed: a G to T substitution encoding a nonsynonymous amino acid change (p.P217L) in a cell line derived from an acral lentiginous melanoma tumor. This altered proline is 3 0 of the HMG binding domain and is evolutionarily conserved from mammals to chicken. Although we were unable to validate that this coding alteration occurred somatically in this sample as normal genomic DNA from this To assess whether SOX10 is required for melanoma cells in vitro, we conducted RNAi-mediated knockdown. Three melanoma cell lines were transduced with 2 different SOX10-specific lentiviral RNAi hairpins (shSOX10) and compared with lines transduced with a nonsilencing control hairpin. One week after infection, the shSOX10 lines showed reduced SOX10 protein levels and the cells became enlarged, flat, and translucent ( Fig. 1A and B) . These cells also showed arrested or slowed growth (Fig. 1C) . Analysis of five additional melanoma lines showed consistent results, with 6 of the 8 lines displaying altered cellular morphology and slowed growth resulting from SOX10 knockdown (data not shown). Three of these 6 lines were selected for further functional analysis: the 0002-ARM and UACC 1022 cell lines, which contain V600E and L597S BRAF mutations, respectively, and the 0380-MMU cell line, which harbors an NRAS Q61K mutation.
To further characterize the arrested growth we observed in the shSOX10 lines, we stained for b-galactosidase (SA-b-Gal), a biomarker of cellular senescence (Fig. 1D ). Significant increases in SA-b-Gal activity were seen in all 3 lines when stably transduced with shSOX10 hairpins (Fig. 1E) , suggesting that loss of SOX10 induces senescence in melanoma cells. Another hallmark of cellular senescence, senescence-associated heterochromatin foci (SAHF), was observed upon chromatin binding protein HP1b immunostaining ( (sh1 and sh2) . B, phase-contrast images of 0380-MMU stable cell lines, one week after infection with nonsilencing control hairpin or SOX10sh1. C, proliferation assays for 0380-MMU, UACC 1022, and 0002-ARM cell lines transduced with nonsilencing control hairpin, sh1, or sh2. Cells were counted in triplicate 1 to 14 days after plating and proliferation assays were conducted at least twice with subsequent infections. D, representative images of 0380-MMU cells stained for SA-b-Gal activity one week after infection with nonsilencing control hairpin, SOX10sh1, and SOX10sh2. E, significant increases in the percentage of SA-b-Gal-positive cells were seen in SOX10sh lines relative to nonsilencing control hairpin lines as determined by Student t test (for 0380-MMU, sh1 P < 7.32 Â 10 À5 , sh2 P < 7.95 Â 10 À3 ; for UACC 1022, sh1 P < Supplementary Fig. S1 ). Upon loss of SOX10 protein, the cells showed more severe punctate staining of HP1b as a result of chromatin rearrangements brought on by senescent fate.
The shSOX10 cells showed no increase in APC-Annexin V staining as compared with controls, indicating no increase in apoptosis (data not shown). Quantitation of the number of cells in each phase of the cell cycle by fluorescence-activated cell sorting (FACS) analysis showed that SOX10 knockdown cells consistently showed a significant increase in the population of cells in G 1 phase (Fig. 2A) , indicative of G 1 arrest and decreased cell-cycle progression. Taken together, these data suggest SOX10 is required for proliferation of melanoma cells.
SOX10 knockdown results in reduced E2F1 and RB levels
The RB-E2F1 complex gates a fundamental checkpoint regulating progression through the G 1 phase of the cell cycle (7). Phosphorylation releases RB from E2F1 during G 1 and is required for the accumulation of transcriptionally active E2F1 (26). Thus we evaluated E2F1 and RB protein levels by Western blot in SOX10 knockdown cells. In all three melanoma lines, SOX10 knockdown led to reduced levels of E2F1 protein and total RB protein (Fig. 2B) . Consistent with these results, we found E2F1 transcript levels decreased upon SOX10 knockdown (Fig. 2C) , however, no change in RB mRNA levels were seen (Fig. 2C ) despite seeing less RB protein. When the degree of RB phosphorylation was evaluated with an antibody specific for RB serine residues Ser807 and Ser811, we observed a decrease in levels of phosphorylated RB (Fig. 2B) . These data suggest that the total RB protein level decreases as a result of a loss of stable phosphorylated RB and are consistent with the G 1 arrest observed. A similar destabilization of RB protein leading to G 1 arrest has been reported in PAX8 knockdown experiments (27) .
shSOX10-induced G 1 arrest is not mediated by p53 signaling
The p53 pathway regulates the G 1 cell-cycle checkpoint, and p53 activation has been shown to result in melanoma cell-cycle arrest (28) . Therefore we measured p53 protein levels in SOX10 knockdown cells. In the 0002-ARM cell line, p53 levels decreased with reduced SOX10 expression, however no change in p53 levels was observed in 0380-MMU cells (Fig. 2B) . For the UACC 1022 line, p53 was undetectable in both the control cells and shSOX10 lines (Fig. 2B) . Sequencing of the TP53 locus in the UACC 1022 line identified a premature stop codon along with loss of heterozygosity (R195X; data not shown), indicating UACC 1022 is null for p53 protein signaling. As growth arrest was observed in all three lines, independent of p53 status, the G 1 arrest observed in shSOX10 cells is not solely mediated through the p53 signaling pathway.
SOX10 knockdown results in decreased MITF and increased CDK inhibitors p21 and p27
As knockdown of MITF in melanoma cell lines has been shown to produce a similar decrease in growth rate and G 1 cellcycle arrest (29) and MITF is a well established downstream transcriptional target of SOX10 (30), we assessed MITF expression upon shSOX10 knockdown. Reduced MITF protein was 
0380-MMU
Fold mRNA expression change Figure 2 . Cell-cycle arrest and expression changes in cell-cycle regulators are observed upon stable loss of SOX10. A, significant increases in G1 cell populations were observed in 0380-MMU, UACC 1022, and 0002-ARM lines stably transduced with SOX10-specific hairpins (sh1 and sh2) relative to lines stably transduced with a nonsilencing control hairpin (NS; Student t test P values were 0380-MMU, sh1 ¼ P < 0.007, sh2 ¼ P < 0.026; UACC 1022 sh1 ¼ P < 0.026, sh2 ¼ 0.17; 0002-ARM sh1 ¼ P < 0.023, sh2 ¼ P < 0.03). FACS analysis on each line was repeated twice with subsequent infections. B, Western blot analysis of the effects of nonsilencing control hairpin, sh1, and sh2 stable transduction in each line on important cellcycle regulatory proteins. C, qRT-PCR of RNA isolated from 0380-MMU nonsilencing control hairpin and sh1 stable lines showed significant changes in SOX10 (P < 0.006), MITF (P < 0.0005), E2F1 (P < 0.005), and p21 (P < 0.016) expression as determined by Student t test. Data are fold change normalized to control and the average of three replicate assays.
observed upon shSOX10 knockdown in both 0380-MMU and 0002-ARM cells (Fig. 2B) , whereas MITF protein expression was undetectable by Western blot analysis in UACC 1022 control cells (Fig. 2B ). Given these altered MITF expression levels, we looked for consistent alterations in G 1 cell-cycle regulators across the three lines. CDK2, itself a downstream target of MITF transactivation (31), decreased in both the 0380-MMU and UACC 1022 shSOX10 cells and increased in the 0002-ARM shSOX10 cells (Supplementary Fig. S2 ). However, no consistent change in total expression level for CDK4, CDK6, or cyclin D1 proteins was observed (Supplementary Fig. S2 ), thus CDK protein expression levels did not provide a unified mechanism to explain the loss of phosphorylated RB protein observed in shSOX10 cells.
We next evaluated protein levels of p16 (CDKN2A), p21 (CDKN1A), and p27 (CDKN1B) following SOX10 knockdown (Fig. 2B) . Lowered MITF levels leading to G 1 arrest have been correlated with an increase in p27 levels (12) and with decreased levels of p21, as MITF directly regulates p21 transcription (32, 33) . We observed moderate p16 expression in 0380-MMU cells; however, p16 levels remained unchanged following SOX10 knockdown. We consistently observed increases in p27 levels in all three cell lines as a result of SOX10 knockdown (Fig. 2B) , similar to previous MITF knockdown studies (12) . However, SOX10 knockdown caused an increase in p21 protein in all three-cell lines (Fig. 2B) , thus showing a distinct difference from the MITF knockdown results.
Altered MITF and p27 gene expression occur before G 1 arrest
To assess changes in transcript levels before G 1 arrest, we conducted a transient, 72-hour siRNA knockdown of SOX10. In both 0380-MMU and UACC 1022 cell lines, siSOX10 knockdown led to decreased SOX10 protein ( Supplementary Fig. S3 ), however, siSOX10 knockdown did not increase SA b-gal activity or the G 1 cell population (Fig. 3A and B) . Consistent with the stable shSOX10 knockdown results, we found transient siSOX10 treatment reduced MITF mRNA in both cell lines, increased p27 mRNA in both cell lines, increased p21 mRNA in 0380-MMU cells (but had no effect on p21 in UACC1022 cells), and had no effect on RB mRNA levels in both lines (Fig. 3C and  D) . E2F1 message changes seemed to be cell-type dependent ( Fig. 3C and D) .
Reduction of SOX10 expression in vivo suppresses melanomagenesis
To assess the role of SOX10 in melanoma progression in vivo, we used a mouse model of Sox10 haploinsufficiency (Sox10 LacZ/þ ; ref.
21) crossed with a Grm1
Tg mouse melanoma model (20) . In human melanomas, glutamate receptor pathway activation is observed in tumors harboring recurrent mutations in the glutamate receptor genes GRM3 (34) and GRIN2A (35) . Similarly, Grm1
Tg mice harbor a transgene insertion that causes overexpression of Grm1, activates the glutamatergic pathway and causes numerous, pigmented nevi at weaning in heterozygous and homozygous mice (Fig. 4A) . Nevi in homozygotes (Grm1 Tg/Tg ) are raised by 2 to 3 months of age and typically necessitate euthanasia by 5 months of age. We crossed Grm1 Tg/Tg mice with Sox10 LacZ/þ mice, then double heterozygotes were backcrossed to Grm1
Tg/Tg mice, thus generating Grm1
Tg/þ and Grm1 Tg/Tg offspring that were also haploinsufficient for Sox10 (Grm1 Tg/þ ;Sox10 LacZ/þ and Grm1 Tg/Tg ; Sox10
LacZ/þ , respectively) along with Grm1
Tg/þ and Grm1
Tg/Tg littermates. The extent of pigmentation and severity of raised tumors visible on the ears of 3-to 5-month-old mice was quantitatively scored and compared among genotypes (Fig.  4A-C) . Sox10 haploinsufficiency significantly reduced the number of pigmented nevi in both Grm1 Tg/þ and Grm1
Tg/Tg mice (P < 0.005), and also the severity of raised nevi in Grm1
Tg/Tg mice (P < 0.05). An extended tumor latency was also observed, with raised tumors first appearing in Grm1
Tg/Tg ; Sox10
LacZ/þ mice at 5 to 6 months versus 2 to 3 months in Grm1
Tg/Tg mice (data not shown). Interestingly, the Grm1
Tg transgene did not suppress the hypopigmentation (belly spots) that is normally observed in Sox10
LacZ/þ mice due to a developmental reduction in melanoblast number ( Fig. 4D and E) . This indicates that Grm1
Tg does not cause a developmental expansion of melanoblasts and suggests that the role of SOX10 in melanoma suppression is independent of its effect on embryonic melanoblast number. Another white spotting allele with a developmental reduction in melanoblasts, Kit
LacZ , was not sufficient to suppress melanoma in Grm1
Tg ( Supplementary Fig.  S4 ), which is consistent with separate roles for SOX10 in developmental melanoblast number and melanoma formation in the Grm1
Tg model.
To understand the role of Mitf in the Sox10
LacZ suppression of Grm1
Tg mouse melanoma lesions, Grm1 Tg/Tg mice were crossed to mice that harbor a transgene disruption that results in a functionally null allele of Mitf. In contrast with the Grm1
Tg/þ ; Sox10
LacZ/þ and Grm1
Tg/Tg ;Sox10 LacZ/þ mice, heterozygosity for the Mitf vga9 allele did not suppress the development of hyperpigmented, raised lesions in the Grm1
Tg/þ ;Mitf vga9/þ and Grm1
Tg/Tg ;Mitf vga9/þ mice ( Supplementary Fig. S4 ). Of note, Mitf vga9/vga9 homozygotes lack melanocytes and thus could not be analyzed (22, 36) . In summary, Sox10 haploinsufficiency is sufficient to suppress the phenotype of Grm1
Tg mice, indicating an essential role of SOX10 in melanoma progression.
Discussion
Melanoma is an aggressive tumor type that progresses rapidly and exhibits resistance to most current therapeutic interventions. Although targeted therapies to known tumor suppressor and oncogenic players in melanoma cells may achieve responses, patients are subject to relapse (37, 38) . This study focuses on the role of SOX10 in melanoma and supports mounting evidence suggesting SOX10 is an important lineagespecific target for patient intervention. Previous studies have detailed broad expression of SOX10 in melanoma tumor samples across various stages of disease, further suggesting a necessity for this protein in melanoma (39) (40) (41) (42) .
Our sequencing analysis reveals a low frequency of intragenic mutations in SOX10, suggesting a preference for wildtype SOX10 protein in melanoma formation and maintenance.
Recent research has shown the rate of "passenger" mutations, propagated by clonal expansion without any growth advantage, is higher in cutaneous melanoma than in solid tumors (43) . This high passenger mutation rate was exemplified in genomic sequencing of 121 melanoma samples, where 518 genes were found to have mutations in more than 10% of melanoma samples (5) . Previously, we identified nine SOX10 mutations from 2 small, distinct melanoma patient cohorts. Data are fold change normalized to nonsilencing control. siSOX10-transfected UACC 1022 cells showed significant changes in expression of SOX10 (P < 0.05), MITF (P < 0.0004), and E2F1 (P < 0.001). siSOX10-transfected 0380-MMU cells showed significant changes in the expression of SOX10 (P < 0.01), MITF (P < 0.007), and E2F1 (P < 0.001); p21 and p27 showed increased expression that did not achieve statistical significance. Data analyzed by Student t test.
We identified 3 of 50 mutations in metastatic samples from individuals enrolled in a single clinical trial and 7 of 55 mutations from primary samples for a combined mutation rate of 8.5%. Of these, only the three mutations identified from samples obtained from the single metastatic cohort of patients were characterized by either an early truncation of SOX10 or an alteration leading to a C-terminal extension of SOX10 and were found to have reduced SOX10 functional activity (10) . Given that the combined mutation rate (8.5%) falls within the range anticipated for melanoma and that all of the confirmed functional mutations were ascertained from one patient cohort, we felt further analysis of the SOX10 locus was warranted.
In this analysis, we increased sample numbers of mucosal and lentiginous melanoma subtypes and increased the diversity of clinical sources from which samples were collected, to reduce the potential for ascertainment bias. From this diverse sample cohort we found only 1 of 153 (<1%) of melanoma samples mutated for SOX10. This rate is consistent with the SOX10 mutation rate identified from recent large scale sequencing of metastatic melanoma (5) . These data show that the SOX10 mutation rate is less than the passenger mutation rate, suggesting the potential preference for wild-type SOX10 protein in melanoma formation and maintenance.
Consistent with this finding, we hypothesize that SOX10 regulates melanoma cell proliferation and cell-cycle regulation via multiple, convergent pathways regulating RB and E2F1 levels. Reduction in SOX10 levels results in increased expression of p21 and p27, inhibitors of CDKs, which regulate multiple, sequential phosphorylation events on RB necessary for cell-cycle progression. The E2F1-RB complex provides a cellular checkpoint for cell-cycle progression out of G 1 . RB in its hypophosphorylated state prevents cells from entering S-phase and arrests them at G 1 . E2F1 level regulation is a key mediator of progression through G 1 , as E2F1 functions to activate downstream targets required for entry into S-phase. As we observed a change in E2F1 RNA levels combined with a senescent cellular phenotype when SOX10 expression was decreased in melanoma cell lines, we postulate that SOX10, or a downstream target, is required for proper regulation of E2F1 and subsequent control of cell proliferation through RB-E2F1 signaling. This is in contrast with what is observed for RB, where RB protein is reduced but transcript expression is unchanged following SOX10 reduction. We cannot exclude the possibility that SOX10 could indirectly stabilize the RB protein to prevent proteasomal degradation. In fact, the reduction in total RB protein may be a result of SOX10-mediated reduction Tg alleles reduces pigmented ear lesions (right two panels). B-C, Grm1 Tg phenotypic severity either alone or in the context of Sox10 haploinsufficiency was quantitatively measured by scoring each individual animal on a scale of 1 to 4 for the extent of pigmentation (B) and burden of raised tumors (C). Sox10 haploinsufficiency significantly reduced pigmented nevi (P < 0.005) in both Grm1
Tg/þ and Grm1 Tg/Tg mice and also the extent to which they were raised (P < 0.05) in Grm1
Tg/Tg mice (Mann-Whitney test with Bonferonni correction). D, no ventral spotting was observed in Grm1
Tg/þ or Grm1 Tg/Tg mice that were also Sox10 þ/þ (left) and the presence of one or two Grm1 Tg/þ alleles did not affect ventral spotting caused by the Sox10
LacZ allele (right; mice shown received a spotting severity score of 2). E, quantitative scoring of belly spots in Sox10
LacZ ; Grm1 Tg/þ , and Sox10
LacZ ; Grm1
Tg/Tg mice showed no significant differences (P ¼ 0.3342; Kruskal-Wallis nonparametric one-way ANOVA).
in E2F1 levels, as reduced levels of active RB have been shown to be a direct consequence of decreased E2F1 expression (44) as well as increased p27 and p21 levels, ultimately resulting in more unstable hypophosphorylated RB protein (45) . Studies involving human melanoma cell lines can be limited because of the heterogeneity and phenotypic variations resulting from context-dependent effects on the genome. The melanoma cell lines described in this study mirror that heterogeneity, showing differences in p53 status, p16 ARF and MITF expression levels, and mutation status of the major oncogenes NRAS and BRAF. Despite these notable variations, a dysregulated cell cycle with altered RB and E2F1 levels was consistently observed upon loss of SOX10 protein. Initially we hypothesized that MITF, which itself is a direct transcriptional target of SOX10, was appropriately poised to be the responsible transcription factor. Although RNAi-mediated reduction of MITF also leads to a senescent morphology and G 1 cell arrest (13) , this occurred in conjunction with a decrease in p21 expression, which was not observed in our study of SOX10 knockdown. These results may have potential implications clinically given the heterogeneity that exists within melanoma tumors. Importantly, the consistent observation that SOX10 is required for proliferation of melanoma cells suggests that SOX10 or its downstream targets are involved in the regulation of cell cycle.
The frequent acquired resistance to current BRAF inhibitors observed in recent clinical trials is mediated by reacquisition of increased MAPK signaling (46) . These results highlight the need for a more comprehensive understanding of all aspects of cell-cycle dysregulation that occurs as a result of increased MAPK signaling in tumors and the need to evaluate additional mechanisms that have the capacity to reduce cell proliferation and tumor formation. We find that SOX10 has a pivotal role in melanoma cell proliferation not only in cell culture, but also in vivo, as Sox10 haploinsufficiency prevents the formation of hyperpigmented lesions observed in the Grm1
Tg mouse melanoma model. A recent study by Shakhova and colleagues reported a similar reduction in tumor formation when SOX10 levels were reduced in the context of the Nras Q61K -driven mouse melanoma model (47) . Together, these studies show that distinct melanoma drivers require SOX10 for tumor formation and maintenance. Both NRAS and GRM1 activate the MAPK and PI3K/AKT signaling pathways, which are fundamental to melanomagenesis. Given that both the Nras Q61K and the Grm1 Tg mouse melanoma models are rescued with Sox10 haploinsufficiency, SOX10 may occupy an important position of regulation of oncogenic cell-cycle progression downstream of one or both of these signaling pathways. Interestingly, the Grm1 Tg mouse melanoma model is not rescued with the Mitf vga9 mouse, suggesting that either this cross did not result in a sufficient loss in Mitf expression, as Mitf vga/þ mice have been shown to exhibit a 50% reduction in melanocyte MITF levels (22) or that SOX10 is involved in key melanoma pathways independent of its regulation of Mitf levels. When these data are combined with the extensive occurrence of SOX10-positive cells in both primary and metastatic tumors (41) , the frequent tumor retention of wild-type SOX10 protein and the effect of reduced SOX10 levels on RB and E2F1 levels, leading to decreased cell-cycle progression and melanoma cell proliferation, SOX10 is revealed as a notable molecule for further assessment as a therapeutic target.
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